myotwin

myotwin, founded in 2023 and headquartered in Germany, is carving a niche in the biotech industry with its pioneering slogan: "For a better and animal-free drug development." The company focuses on revolutionizing pre-clinical cardiac research by offering science-as-a-service solutions using human heart muscle organoids. This innovative approach promises reproducible, high-detail results vital for drug testing and research, substantially accelerating development speed and reducing reliance on animal testing.

The company's services are particularly beneficial for biotech, pharmaceutical, and academic entities aiming to de-risk and expedite their pre-clinical stages, fostering a more ethical research landscape. myotwin is actively seeking additional investments, research-driven customers, and working students to further refine its product offerings and expand its market presence. Their mission to transform scientific research practices aligns with growing demands for sustainable and ethical solutions in the industry.